Kirt Munson
Family · Toledo, OHNPI 1396230124
Payments from drug & device makers
Across 1,401 payments — averaging $76.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$69K
- Biohaven Pharmaceuticals, Inc.$15K
- Pfizer$10K
- Biohaven Pharmaceutical Holding Company Ltd.$4K
- Teva Pharmaceuticals USA, Inc.$1K
- UCB, Inc.$1K
- plus $7K from 35 others
What the payments were for
- Consulting fees$6751%
- Speaking & faculty fees$83,46578%
- Travel & lodging$1,3851%
- Food & beverage$21,81720%
- Education$2900%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$107,632 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 28 | $262,827 |
| QuliptaAtogepant | 148 | $195,242 |
| Nurtec OdtRimegepant Sulfate | 71 | $134,775 |
| UbrelvyUbrogepant | 58 | $93,574 |
| Aimovig AutoinjectorErenumab-Aooe | 48 | $44,592 |
| ReyvowLasmiditan Succinate | 51 | $40,648 |
| Ajovy AutoinjectorFremanezumab-Vfrm | 25 | $34,340 |
| Emgality PenGalcanezumab-Gnlm | 29 | $34,002 |
| XcopriCenobamate | 16 | $23,024 |
| Emgality SyringeGalcanezumab-Gnlm | 11 | $7,354 |
| Tegretol XrCarbamazepine | 12 | $7,250 |
| Pregabalin | 112 | $5,707 |
| Sumatriptan Succinate | 116 | $4,693 |
| RizatriptanRizatriptan Benzoate | 90 | $3,390 |
| Gabapentin | 202 | $2,681 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $69,187 | $288,816206 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $1,409 | $262,82728 claims |
| PfizerNurtec Odt | $10,407 | $134,77571 claims |
| Lilly USA, LLCReyvow | $770 | $40,64851 claims |
| SK Life Science, Inc.Xcopri | $918 | $23,02416 claims |
| Upsher-smith Laboratories LLCTopiramate | $252 | $1,624149 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.
Other family in Toledo
- Sheri LukeToledo$31K
- Kyle PatchenToledo$25K
- Alexander NorwoodToledo$17K
- Eileen FauldsLewis Center$991K
- Leigh Ann PanschDayton$670K
- Natalie BelliniMayfield Heights$582K
- Kaitlyn LovettMontgomery$286K
- Amy RossDayton$281K
- Renee OttSandusky$179K
- Megan MillerSpringfield$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.